By Ben Wylie
The market for mRNA (messenger Ribonucleic Acid) vaccine technology is expanding rapidly. mRNA vaccines stimulate the immune response in a patient’s body. Instead of the vaccine containing a weakened/inactivated form of the virus, the vaccine contains genetic material coding for a disease-specific protein to the virus. Though manufacturing, mRNA technology comes with a list of challenges, the biggest obstacle being achieving compliance with GMP Annex 1 regulations. Here, we dive into the compliance issue and explain how companies who want to use mRNA vaccine technology can address challenges through the use of single-use technologies (SUTs).